Zoetis Inc. (ETR:ZOE)

Market Cap	47.53B -34.3%
Revenue (ttm)	8.01B +2.7%
Net Income	2.26B +9.1%
EPS	5.06 +11.6%
Shares Out	n/a
PE Ratio	21.04
Forward PE	19.39
Dividend	1.76 (1.63%)
Ex-Dividend Date	Jan 20, 2026

Volume	1,351
Average Volume	852
Open	107.40
Previous Close	107.82
Day's Range	107.00 - 109.24
52-Week Range	97.50 - 170.22
Beta	0.97
RSI	57.83
Earnings Date	Feb 13, 2026

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1950
• Employees: 13,800
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: ZOE

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.

Financial numbers in USD